Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|April 2, 2017
- Pharmaceutical Technology-04-02-2017
- Volume 41
- Issue 4
Nanoparticle Deagglomeration Technology
The Thinky PR-1 Nanoparticle Dispersion Machine from Intertronics is a desktop unit that can disperse carbon nanotubes (CNT), graphene, and other 2D nanomaterials within a closed container.
The Thinky PR-1 Nanoparticle Dispersion Machine from Intertronics is a desktop unit that can disperse carbon nanotubes (CNT), graphene, and other 2D nanomaterials within a closed container. The dispersion is consistent, highly reproducible, and is typically accomplished in a few minutes. The Thinky PR-1 uses mechanical rotation and multi-directional ultrasonics to achieve a rapid and even particle dispersion. The machine has a temperature limit control in the ultrasonic bath to counter the temperature rise of water and materials as a result of ultrasonic energy, avoiding changes in physical material properties. The system is compatible with quantities as small as a 5 mL capacity vial to a 200 mL capacity stainless steel container. The Thinky PR-1 can be used for applications in drug delivery, imaging, tissue engineering, and biosensors.
Articles in this issue
over 9 years ago
EU–US Mutual Recognition Agreement on GMP Inspectionsover 9 years ago
Evaluating Progress in Analytical Quality by Designover 9 years ago
Staffing for China’s Rapidly Growing Biomanufacturing Industryover 9 years ago
Making the Most of Internal Auditsover 9 years ago
FDA Quality Metrics Initiative Challenges Manufacturersover 9 years ago
Multi-Functional Mixing System for Pastes, Creams, and Gelsover 9 years ago
Mass Spectrometry System Standardizes WorkflowsRelated to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5